SCHEMBL22579239

SCHEMBL22579239

Cc1cc(/C=C/C(=O)O)ccc1-c1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 3/20 0.51
▸ MAPT P10636 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ GPR119 Q8TDV5 3/20 0.45
▸ PDK2 Q15119 1/20 0.45
▸ HDAC1 Q13547 1/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ RET P07949 1/20 0.43
▸ CTSS P25774 1/20 0.43
▸ CTSK P43235 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ALK Q9UM73 1/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ ESRRB O95718 1/20 0.41
▸ ESR1 P03372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22579238 0.90 ABCB1 (0.51) ABCB1MAPTALDH1A1LMNAGPR119
SCHEMBL22579225 0.88 MAPT (0.51) ABCB1MAPTALDH1A1LMNAGPR119
SCHEMBL22641699 0.82 ABCB1 (0.43) ABCB1MAPTALDH1A1LMNAGPR119
SCHEMBL25201600 0.80 ABCB1 (0.60) ABCB1MAPTALDH1A1LMNAGPR119
SCHEMBL1481986 0.80 ABCB1 (0.60) ABCB1MAPTALDH1A1LMNAGPR119
SCHEMBL22579236 0.80 ABCB1 (0.41) ABCB1MAPTALDH1A1LMNAGPR119
SCHEMBL22579252 0.78 RET (0.52) RET
SCHEMBL5573222 0.75 MAPT (0.76) MAPTALDH1A1LMNAGPR119PDK2
SCHEMBL22579359 0.75 PDK2 (0.48) ABCB1MAPTALDH1A1LMNAGPR119
SCHEMBL4719115 0.75 ABCB1 (0.56) ABCB1MAPTALDH1A1LMNAGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200331882-A1 COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) 2020-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331882-A1 COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF HDAC1, HDAC3, HDAC11 ABCB1 1271/4885MAPT 4614/4885ALDH1A1 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback